CROI 2024 Abstract eBook

Abstract eBook

Abstract Process

ABSTRACT PROCESS Scientific Categories B asic Science A Virology of HIV, SARS-CoV-2, or Mpox Virus B Pathogenesis of HIV, SARS-CoV-2, or Mpox Virus: Human Studies and Animal Models C Host Immune Responses, Vaccines, and Immunotherapies: HIV, SARS-CoV-2, or Mpox Virus D HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy G Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 or Mpox Virus in Adults H Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults I Hepatitis Viruses and Liver Complications in Adults J HIV-Related Malignancies and Tumor Viruses K Cardiovascular Complications of HIV Infection and Antiretroviral Therapy L Other Complications of HIV Infection and Antiretroviral Therapy in Adults M Clinical Manifestations and Outcomes of SARS-CoV-2, Including Long COVID, and Mpox Infections N Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults O Maternal and Fetal HIV, SARS-CoV-2, and Mpox Virus P Childhood and Adolescent HIV, SARS-CoV-2, or Mpox Virus Epidemiology/Public Health Q Epidemiology of HIV, COVID-19, and Mpox R Testing for HIV, COVID-19, and Mpox in Adults: New Tests, Population Studies, and Scale-Up s E Neuropathogenesis and Neurologic Complications of HIV and SARS-CoV-2 Infection and Neurologic Complications of HIV in Adults Clinical F Clinical Pharmacology in Adults S Prevention of HIV, COVID-19, and Mpox in Adults T Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults U Implementation and Scale-Up of Prevention and Treatment for HIV, and Impact of COVID-19 and Mpox on HIV-Related Programs

For more information, visit the CROI Abstract Categories webpage. Note, abstracts that were submitted in categories designated with the letters C, S, U, and W were integrated into other categories. Example citation: Smith I, Jones RM, Peters S, et al. Randomized controlled trial in HIV infection [CROI Abstract 1261]. Abstracts From CROI 2024 Conference on Retroviruses and Opportunistic Infections. CROI 2024 Abstract eBook. 2024;583. Note: These abstracts were current at the time they were submitted, which may have been months before the start of CROI. For the most up-to-date data, please view the posters and oral abstract presentations on the conference app. To search for specific word or term, presenters, or authors on this document, hold the “Ctrl” and press the “F” keys on your keyboard to prompt a word search. CROI conference materials (including, but not limited to, the CROI Program Guide, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce any part of CROI materials (such as an abstract as formatted in the CROI Abstract eBook) must be obtained from the CROI Conference Manager, the International Antiviral Society–USA (IAS–USA). However, study data are the property of the author(s) and study sponsors as relevant. For more information, please email CROIabstracts@iasusa.org. Abstract Numbering: Presentation summaries for invited sessions begin with abstract 1. Oral abstracts begin at abstract 100. Poster abstracts begin at 300. Abstract numbers 51 to 99 and 213 to 299 were intentionally omitted to accommodate this numbering. Similarly, abstracts that were withdrawn are marked as such next to their preserved number. Abstract Content Author names, institutions, titles, and abstracts in the CROI Program Guide, Abstract eBook, Conference App, and other materials are presented largely as provided by the submitting author. THE SUBMITTING AUTHOR IS RESPONSIBLE FOR ENSURING THAT ALL COAUTHORS HAVE REVIEWED AND APPROVED THE ABSTRACT before submission and for providing complete and accurate contact information for all authors, including email addresses. .

Abstract Process

4

CROI 2024